Ketamine Trials Are Enrolling the Patients They Used to Exclude. This One Has a Placebo Arm
Vanderbilt has funding to test IV ketamine for depression in people with mild cognitive impairment or early Alzheimer’s, the medical center announced Wednesday. The result is years away. What makes it worth noting now is who it enrolls, and that it has a control arm.
Trials move slowly. The cost side of a clinic does not have to. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The trial | KeTADiD, Ketamine for Treatment of Alzheimer’s Disease related Depression |
| Who runs it | Patricia Andrews, MD, who directs geriatric psychiatry at Vanderbilt |
| Who can enroll | Adults over 60 with major depression plus MCI or mild dementia, confirmed on biomarkers |
| The protocol | Four monitored infusions of ketamine or placebo, twice weekly for two weeks |
| The span | 10 to 14 weeks, with five in-person visits and eight phone calls |
| Timing | Enrollment is slated to begin in December |
What the Trial Will Actually Do
Participants are men and women over 60 with major depressive disorder, plus either mild cognitive impairment or mild dementia. Alzheimer’s pathology has to be confirmed on biomarkers.
Each receives four monitored IV infusions, twice a week for two weeks. Half get ketamine and half get placebo.
The study runs 10 to 14 weeks in total, built around five in-person visits and eight phone calls.
The stated risks are raised blood pressure and confusion. Both resolve after the infusion.
The Exclusion That Is Coming Down
People with neurodegenerative disease have been kept out of this research for years, on the reasonable concern that nobody knew how they would respond.
That is changing quickly. A UCSF group dosed twelve Parkinson’s patients with psilocybin and reported no serious adverse events, and a separate Berkeley group has been testing psilocybin in the aging brain.
This is the third population in a year to get access to a drug class that had written it off. Vanderbilt is the one adding a control group.
Why the Placebo Arm Is the Story
Andrews points to two pilot studies as the reason to run this at all. One gave repeated infusions to adults over 60 and reported improvement in depression and executive function. Another gave a single infusion to patients with MCI.
Then she says the quiet part out loud. Both studies were open label, she notes, and therefore did not compare ketamine with placebo.
“These findings provide preliminary evidence but do not establish efficacy,” Andrews said.
That is a researcher naming the weakness in her own supporting literature, in her own press release. It is also the whole argument for the trial she is about to run.
The Question the Announcement Leaves Open
Ketamine is unusually hard to blind. Patients generally know when they have received it, which can turn a placebo-controlled trial into an unblinded one in practice.
Trials that take this seriously often use midazolam as an active comparator rather than saline, so the control group feels something too.
The announcement says placebo without specifying which. The trial is not yet posted to the public registry, so the protocol is not available to check.
That single design choice will decide how much the result is worth. It is the first thing to look for when the registration appears.
Why Depression Here Is Not Just Depression
Andrews makes a specific argument about timing that is worth following. Depression is common in these patients, and it also raises the risk of cognitive decline.
Standard treatment is SSRIs and SNRIs, which she describes as having limited efficacy in this group.
Her sharper point is about access to other care. Severe depression, she says, interferes with a patient’s capacity to discuss treatment options.
That can delay the newer drugs that slow the disease itself. On that reading, treating the depression faster is not only about mood. It is about reaching the window where disease-modifying therapy still helps.
What a Clinic Should Take From This
Nothing clinically, yet. This is a safety and tolerability trial that has not enrolled its first participant.
What is useful is the direction. If ketamine clears a controlled trial in an older cognitively impaired population, the pool of people who might be offered it grows substantially.
Andrews has already said that a positive result would lead to a larger multisite randomized trial, measuring durability and longer-term effects on cognition and function.
Families asking about this now should be pointed at the trial rather than at an infusion chair. Enrollment information is in the Vanderbilt announcement, through its Memory and Aging Clinic.
A Trial Worth Watching, Not Citing
There is no finding here. There is a funded protocol, a candid researcher and a population that had been ruled out of this research entirely.
The useful date is December, when enrollment opens, and whenever the registration posts with the comparator named.
Patients looking for supervised care can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not medical advice. Ketamine is not approved by the FDA for depression in Alzheimer’s disease or mild cognitive impairment, and this trial has not begun enrolling.
